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21.91%, p< 0.01), compared to those without a PD diagnosis. The PD cohort also 
incurred significantly higher skilled nursing facility ($6,458 vs. $5,182, p= 0.03), DME 
($344 vs. $206, p< 0.01) and pharmacy costs ($6,025 vs. $4,998, p< 0.0001) compared 
to the comparison cohort. ConClusions: Study results suggest that patients 
diagnosed with PD incurred significantly higher costs and had higher resource 
utilization than those without a PD diagnosis.
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objeCtives: To describe the medical and non-medical direct costs of PD in rela-
tion to the total direct cost and its variation with disease severity during 4 years 
of follow-up. Methods: A descriptive, observational, longitudinal study in PD 
patients belonging to the ELEP study (2007-2010). Data on disease severity and use 
of resources were collected for three consecutive months, yearly, for 4 years. Direct 
medical (funded medical equipment, medications and medical assistance) and 
direct non-medical costs (alternative care, home assistance, non-funded medical 
equipment and medications) for 4 years depending on severity by Hoehn and Yahr 
(HY) was described. Costs were estimated by multiplying rates obtained from the 
database Oblikue (http://www.oblikue.com) and pharmacy costs from the BotPlus 
Web (https://botplusweb.portalfarma.com) by the number of resources used, 
updated to Spanish € , 2012. Results: 198 patients were included. Average age: 
63±11 years, 50% male, mean PD duration of 8±6 years. Mild (HYI-II) and moderate 
(HYIII) PD varied from 76% and 21% to 64% and 29%, respectively during follow-up. 
Total direct cost was higher in severe stages, being in year 4, € 1,477.32 HYI (95%CI: 
219.55-2,735.10) and € 3,606.66 HYIV (95%CI: 893.97-6,319.35) compared to year 1, 
€ 1,093.32 HYI (95%CI: 624.99-1,561.65) to € 2,656.27 HYIV (95%CI: -53.14-5,365.68). 
Direct medical costs ranged from € 886.62 (95%CI: 475.13-1,298.11) HYI and € 2,376.30 
HYIV (95%CI: -53.12-4,805.73) in year 1 to € 909.96 HYI (95%CI: 942.43-1,327.49) and 
€ 2,768.49 HYIV (95%CI: 34.21-5,502.76) at year 4. Direct non-medical cost variation 
were determined by PD temporal evolution, increasing between year 1 and 4 within 
each stage, € 723.47 to € 4,255.20 HYI and € 653.27 to € 1,676.35 HYIV. ConClusions: 
The economic burden of PD rises with duration and severity of the disease, progres-
sively increasing the direct, medical and non-medical costs. Besides to improve 
patients’ HRQoL, therapies aimed at controlling the symptoms severity will favor a 
more efficient management of the disease.
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objeCtives: Portuguese financing model set for Multiple Sclerosis (MS) establishes 
a comprehensive price of 1.031,65€ per remitting patient/month. This study aimed 
to estimate global and individual direct costs of MS in Portugal and evaluate the 
coverage of MS Financing model for Relapsing-Remiting Multiple Sclerosis (RRMS) 
patients. Methods: A cost-of-illness (COI) approach was taken to assess direct 
costs/per RRMS patient by EDSS level, both for remission and relapse status using 
Delphi methodology for clinical practice measurement. Portuguese epidemiological 
data available for prevalence and relative distribution by EDSS level was used to 
estimate global MS costs and an average cost per RRMS patient. Results: The global 
cost for RRMS in Portugal is estimated to be approximately 83M€ /year for patients 
treated with 1st line Disease Modifying Therapies (DMT). Relapse treatment costs 
account for 8M€ . Direct costs estimated per disability level show that disability 
levels are directly related with expenditure in RRMS patients in remission (EDSS≤ 3: 
10.754,90€ ; 3,5≤ EDSS≤ 4,5: 20.113,99€ ; 5≤ EDSS≤ 6: 21.170,36€ ; EDSS≥ 6,5: 24.945,94€ ). 
The same was observed for relapse cost (EDSS≤ 3: 4.952,23€ ; 3,5≤ EDSS≤ 4,5: 5.568,49€ ; 
5≤ EDSS≤ 6: 8.801,03€ ; EDSS≥ 6,5: 9.265,31€ ). An average cost of 14.563,48€ per 
RRMS patient was estimated based on Portuguese EDSS epidemiological distribu-
tion. ConClusions: Current comprehensive financing model per patient does 
not cover the costs associated with an average RRMS patient. We demonstrated 
that considering the epidemiological distribution per EDSS level there is a gap of 
2.183,68€ (14.563,48€ vs. 12.379,80€ ). In addition, it was estimated that 2nd line high 
efficacy treatments (additional investment of 76% in treatment costs) may lead up to 
4.3M€ savings in relapse treatment total costs by reducing annualized relapse rate. 
Further studies should be developed to assess the budget impact of 2nd line high 
efficacy treatments on disability progression since lower EDSS scales are associated 
with less expenditure per patient (EDSS≤ 3: 10.754,90€ vs EDSS ≥ 6,5: 24.945,94€ ).
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objeCtives: Multiple Sclerosis (MS) is a chronic and progressive which represents 
a catastrophic payment to patient, society and health care system. Iran, differing 
to the other countries in Middle- east, is considered to have a medium to high 
prevalence of MS. Although much is known about the MS cost in the world, there 
is a very paucity of the MS cost study in Iran. The aim of study was to estimate the 
costs and QOL in MS individuals and determine whether these costs increase as 
disability progress. Methods: We studied 160 MS patients who attended in the MS 
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objeCtives: To assess the cost-effectiveness of abobotulinumtoxinA, onabotuli-
numtoxinA, incobotulinumtoxinA and local standard therapy (oral muscle relaxers) 
in patients with post-stroke spasticity in Russia for 1-year period. Physical therapy 
was used in all therapy schemes. Methods: A decision tree was used to simulate 
the effects of abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA and 
standard therapy. The data on drugs efficacy (measured as decrease in the Modified 
Ashworth scale (MAS) score) was obtained from available clinical trials [1-3]. The fol-
lowing costs were taken into account:, the costs of BTA and other drugs, costs of inpa-
tient and outpatient care in the Russian Federation, costs of adverse events, disability 
pensions, GDP loss due to post-stroke spasticity. Costs of BTA and other drugs were 
taken from the essential drug list and the database of drugs prices. Medical care costs 
were estimated from the Standard of treatment of stroke consequences developed by 
Ministry of Health of the Russian Federation. Costs of adverse events were calculated 
basing on Russian clinical guidelines and database of drugs prices. Disability pen-
sions were taken from Russian Pension Fund database. GDP loss was based on the 
GDP information from World Bank. Cost-effectiveness ratio (CER) of BTA and stand-
ard therapy was calculated and compared in four treatment schemes. Results: 
Therapy with abobotulinumtoxinA showed most prominent decrease of Modified 
Ashworth score equal to 1,67, as for onabotulinumtoxinA – 1,17, incobotulinum-
toxinA – 0,87, standard therapy – 0,67. The calculated CER in USD per 1 spastic-
ity decrease point according to MAS was lowest for abobotulinumtoxinA (389524 
RUB/11356 $) in comparison with onabotulinumtoxinA (635631 RUB/18532 $); inco-
botulinumtoxinA (798750 RUB/23287 $) and standard therapy (873312 RUB/25461 $). 
ConClusions: Therapy conversion to abobotulinumtoxinA comparing with stand-
ard therapy, onabotulinumtoxinA and incobotulinumtoxinA was associated with 
decrease of spasticity. Transfer to abobotulinumtoxinA is considered cost-effective 
in patients with post-stroke spasticity, given a cost-effectiveness ratio 389524 
RUB/11356 $.
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objeCtives: Deep Brain Stimulation (DBS) for the treatment of advanced 
Parkinson’s Disease (PD) is a therapy supported with high level evidence, however 
no direct comparative studies exist of DBS against other therapy options, such as 
continued subcutaneous apomorphine infusion (CSAI) exists. The objective of this 
study was to evaluate the 5-year cost profiles of two therapies for advanced PD, DBS 
and CSAI, from a UK payer perspective. Methods: A Markov model, previously used 
to model cost-effectiveness of DBS+BMT vs BMT alone (Eggington 2013), served to 
evaluate the cost profile of DBS and CSAI over five-years. Equal efficacy of the two 
therapies was assumed. The cost analysis covered: device acquisition, implanta-
tion, adverse event management, concomitant drug use, device replacements and 
follow-up. Cost data were taken from UK national tariffs, combined with device/
drug price lists and data from previous economic studies of interventions for PD. 
Disease-related inputs were based on recent studies of DBS and CSAI in patients 
with advanced PD, plus long-term data from the literature. Costs were discounted 
at 3.5% per annum. Results: Total discounted costs over 5 years were £69,566 and 
£80,843 for DBS and CSAI, respectively, leading to cost savings of £11,277 of DBS 
compared to CSAI over 5 years. DBS is cost saving compared to CSAI from 3 years 
onwards, with the initial costs of DBS device acquisition shown to be offset by the 
on-going provision of CSAI. ConClusions: The results indicate that DBS requires 
less health care resources than CSAI over five-years. Comparative clinical data are 
needed to formally assess the relative cost-effectiveness of the two interventions.
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objeCtives: To examine the health care utilizations and costs of long-term care 
facility patients diagnosed with Parkinson’s disease (PD). Methods: Patients 
diagnosed with PD (International Classification of Disease, 9thRevision, Clinical 
Modification [ICD-9-CM] diagnosis code 332) were identified using the Minimum 
Data Set (MDS) linked to 5% Medicare data from 01JAN2009 through 31DEC 2010. 
The initial diagnosis date was designated as the index date. A comparison cohort 
was created for patients without a PD diagnosis, using 1: 1 propensity score match-
ing (PSM) to control for age, region, gender, index year and baseline Charlson 
Comorbidity Index score. The index date for the comparison group was randomly 
chosen to reduce selection bias. Patients in both cohorts were required to be at 
least age 65 years, have at least two consecutive quarterly assessments in MDS 
data in the 6 months prior to the index date, and have continuous medical and 
pharmacy benefits 1 year before and after index date. Study outcomes, (health 
care costs and utilizations) were compared between the disease and comparator 
cohorts, based on the matched sample. Results: After applying PSM, a total of 
986 patients were included in each group (diseased and comparator cohorts), and 
baseline characteristics were balanced. A higher percentage of patients with PD 
had inpatient admissions (35.09% vs. 30.32%, p= 0.02), outpatient visits (93.91% 
vs. 89.45%, p< 0.001) and durable medical equipment (DME) utilization (27.69% vs. 
